Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Jul 15;98(2):365–371. doi: 10.1172/JCI118801

Liver cirrhosis induces renal and liver phospholipase A2 activity in rats.

B S Vishwanath 1, F J Frey 1, G Escher 1, J Reichen 1, B M Frey 1
PMCID: PMC507439  PMID: 8755646

Abstract

Maintenance of renal function in liver cirrhosis requires increased synthesis of arachidonic acid derived prostaglandin metabolites. Arachidonate metabolites have been reported to be involved in modulation of liver damage. The purpose of the present study was to establish whether the first enzyme of the prostaglandin cascade synthesis, the phospholipase A2(PLA2) is altered in liver cirrhosis induced by bile duct excision. The mRNA of PLA2(group I and II) and annexin-I a presumptive inhibitor of PLA2 enzyme was measured by PCR using glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal standard. The mean mRNA ratio of group II PLA2/GAPDH was increased in liver tissue by 126% (P < 0.001) and in kidney tissue by 263% (P < 0.006) following induction of liver cirrhosis. The increase in group II PLA2 mRNA in cirrhotic animals was reflected by an increase in PLA2 protein and enzyme activity in both liver and kidney tissues. Since the mRNA of group I PLA2 was not detectable and Group IV PLA2 activity measured in liver and kidney tissue samples was very low and not changed following induction of cirrhosis, it is likely that the major PLA2 activity measured in liver and kidney corresponds to group II PLA2 enzyme. The mean mRNA ratio of annexin-I/GAPDH was increased in liver tissue by 115% (P < 0.05) but unchanged in kidney tissue following induction of cirrhosis. The protein content of annexin-I and -V were not affected by bile duct excision in liver and kidney tissue indicating that upregulation of group II PLA2 activity was not due to downregulation of annexin-I or -V. Group II PLA2 activity of glomerular mesangial cells stimulated by interleukin-1 beta was enhanced by bile juice and various bile salts. In conclusion, activity of group II PLA2 is upregulated partly due to enhanced transcription and translation in cirrhosis and is furthermore augmented by elevated levels of bile salts.

Full Text

The Full Text of this article is available as a PDF (208.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AMES R. P., BORKOWSKI A. J., SICINSKI A. M., LARAGH J. H. PROLONGED INFUSIONS OF ANGIOTENSIN II AND NOREPINEPHRINE AND BLOOD PRESSURE, ELECTROLYTE BALANCE, AND ALDOSTERONE AND CORTISOL SECRETION IN NORMAL MAN AND IN CIRRHOSIS WITH ASCITES. J Clin Invest. 1965 Jul;44:1171–1186. doi: 10.1172/JCI105224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Andreatta-van Leyen S., Romero M. F., Khosla M. C., Douglas J. G. Modulation of phospholipase A2 activity and sodium transport by angiotensin-(1-7). Kidney Int. 1993 Nov;44(5):932–936. doi: 10.1038/ki.1993.334. [DOI] [PubMed] [Google Scholar]
  3. Arroyo V., Bosch J., Mauri M., Ribera F., Navarro-López F., Rodés J. Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites. Eur J Clin Invest. 1981 Jun;11(3):221–229. doi: 10.1111/j.1365-2362.1981.tb01844.x. [DOI] [PubMed] [Google Scholar]
  4. Blackwell G. J., Carnuccio R., Di Rosa M., Flower R. J., Parente L., Persico P. Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature. 1980 Sep 11;287(5778):147–149. doi: 10.1038/287147a0. [DOI] [PubMed] [Google Scholar]
  5. Bosch J., Arroyo V., Betriu A., Mas A., Carrilho F., Rivera F., Navarro-Lopez F., Rodes J. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology. 1980 Jan;78(1):92–99. [PubMed] [Google Scholar]
  6. Brater D. C., Anderson S. A., Brown-Cartwright D. Reversible acute decrease in renal function by NSAIDs in cirrhosis. Am J Med Sci. 1987 Sep;294(3):168–174. doi: 10.1097/00000441-198709000-00007. [DOI] [PubMed] [Google Scholar]
  7. Bruix J., Bosch J., Kravetz D., Mastai R., Rodés J. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology. 1985 Feb;88(2):430–435. doi: 10.1016/0016-5085(85)90503-7. [DOI] [PubMed] [Google Scholar]
  8. Bursch W., Schulte-Hermann R. Cytoprotective effect of the prostacyclin derivative iloprost against liver cell death induced by the hepatotoxins carbon tetrachloride and bromobenzene. Klin Wochenschr. 1986;64 (Suppl 7):47–50. [PubMed] [Google Scholar]
  9. Büchler M., Malfertheiner P., Schädlich H., Nevalainen T. J., Friess H., Beger H. G. Role of phospholipase A2 in human acute pancreatitis. Gastroenterology. 1989 Dec;97(6):1521–1526. doi: 10.1016/0016-5085(89)90398-3. [DOI] [PubMed] [Google Scholar]
  10. Chang S. W., Feddersen C. O., Henson P. M., Voelkel N. F. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest. 1987 May;79(5):1498–1509. doi: 10.1172/JCI112980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  12. Cirino G., Peers S. H., Flower R. J., Browning J. L., Pepinsky R. B. Human recombinant lipocortin 1 has acute local anti-inflammatory properties in the rat paw edema test. Proc Natl Acad Sci U S A. 1989 May;86(9):3428–3432. doi: 10.1073/pnas.86.9.3428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Clemente C., Bosch J., Rodés J., Arroyo V., Mas A., Maragall S. Functional renal failure and haemorrhagic gastritis associated with endotoxaemia in cirrhosis. Gut. 1977 Jul;18(7):556–560. doi: 10.1136/gut.18.7.556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Daoud F. S., Reeves J. T., Schaefer J. W. Failure of hypoxic pulmonary vasoconstriction in patients with liver cirrhosis. J Clin Invest. 1972 May;51(5):1076–1080. doi: 10.1172/JCI106899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Davidson E. W., Dunn M. J. Pathogenesis of the hepatorenal syndrome. Annu Rev Med. 1987;38:361–372. doi: 10.1146/annurev.me.38.020187.002045. [DOI] [PubMed] [Google Scholar]
  16. Davidson F. F., Dennis E. A., Powell M., Glenney J. R., Jr Inhibition of phospholipase A2 by "lipocortins" and calpactins. An effect of binding to substrate phospholipids. J Biol Chem. 1987 Feb 5;262(4):1698–1705. [PubMed] [Google Scholar]
  17. DiBona G. F. Prostaglandins and nonsteroidal anti-inflammatory drugs. Effects on renal hemodynamics. Am J Med. 1986 Jan 17;80(1A):12–21. doi: 10.1016/0002-9343(86)90928-9. [DOI] [PubMed] [Google Scholar]
  18. Dunn M. J. Role of eicosanoids in the control of renal function in severe hepatic disease. Gastroenterology. 1984 Dec;87(6):1392–1395. [PubMed] [Google Scholar]
  19. Elsing C., Reichen J., Marti U., Renner E. L. Hepatocellular Na+/H+ exchange is activated at transcriptional and posttranscriptional levels in rat biliary cirrhosis. Gastroenterology. 1994 Aug;107(2):468–478. doi: 10.1016/0016-5085(94)90173-2. [DOI] [PubMed] [Google Scholar]
  20. Flower R. J., Blackwell G. J. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature. 1979 Mar 29;278(5703):456–459. doi: 10.1038/278456a0. [DOI] [PubMed] [Google Scholar]
  21. Frey B. M., Frey F. J., Lingappa V. R., Trachsel H. Expression of human recombinant lipocortin I in a wheat-germ cell-free system and Xenopus oocytes. Lipocortin is not secreted. Biochem J. 1991 Apr 1;275(Pt 1):219–225. doi: 10.1042/bj2750219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Glaser K. B., Asmis R., Dennis E. A. Bacterial lipopolysaccharide priming of P388D1 macrophage-like cells for enhanced arachidonic acid metabolism. Platelet-activating factor receptor activation and regulation of phospholipase A2. J Biol Chem. 1990 May 25;265(15):8658–8664. [PubMed] [Google Scholar]
  23. Goulding N. J., Guyre P. M. Glucocorticoids, lipocortins and the immune response. Curr Opin Immunol. 1993 Feb;5(1):108–113. doi: 10.1016/0952-7915(93)90089-b. [DOI] [PubMed] [Google Scholar]
  24. Green J., Better O. S. Systemic hypotension and renal failure in obstructive jaundice-mechanistic and therapeutic aspects. J Am Soc Nephrol. 1995 May;5(11):1853–1871. doi: 10.1681/ASN.V5111853. [DOI] [PubMed] [Google Scholar]
  25. Gross J. B., Jr, Reichen J., Zeltner T. B., Zimmermann A. The evolution of changes in quantitative liver function tests in a rat model of biliary cirrhosis: correlation with morphometric measurement of hepatocyte mass. Hepatology. 1987 May-Jun;7(3):457–463. doi: 10.1002/hep.1840070308. [DOI] [PubMed] [Google Scholar]
  26. Guarner F., Boughton-Smith N. K., Blackwell G. J., Moncada S. Reduction by prostacyclin of acetaminophen-induced liver toxicity in the mouse. Hepatology. 1988 Mar-Apr;8(2):248–253. doi: 10.1002/hep.1840080210. [DOI] [PubMed] [Google Scholar]
  27. Guarner F., Guarner C., Prieto J., Colina I., Quiroga J., Casas J., Freixa R., Rosello J., Gelpi E., Balanzo J. Increased synthesis of systemic prostacyclin in cirrhotic patients. Gastroenterology. 1986 Mar;90(3):687–694. doi: 10.1016/0016-5085(86)91124-8. [DOI] [PubMed] [Google Scholar]
  28. Hagmann W., Steffan A. M., Kirn A., Keppler D. Leukotrienes as mediators in frog virus 3-induced hepatitis in rats. Hepatology. 1987 Jul-Aug;7(4):732–736. doi: 10.1002/hep.1840070419. [DOI] [PubMed] [Google Scholar]
  29. Hashizume M., Inokuchi K., Tanaka K. The role of prostacyclin in patients with portal hypertension. Liver. 1985 Apr;5(2):89–93. doi: 10.1111/j.1600-0676.1985.tb00220.x. [DOI] [PubMed] [Google Scholar]
  30. Heinrikson R. L., Krueger E. T., Keim P. S. Amino acid sequence of phospholipase A2-alpha from the venom of Crotalus adamanteus. A new classification of phospholipases A2 based upon structural determinants. J Biol Chem. 1977 Jul 25;252(14):4913–4921. [PubMed] [Google Scholar]
  31. Ishizaki J., Ohara O., Nakamura E., Tamaki M., Ono T., Kanda A., Yoshida N., Teraoka H., Tojo H., Okamoto M. cDNA cloning and sequence determination of rat membrane-associated phospholipase A2. Biochem Biophys Res Commun. 1989 Aug 15;162(3):1030–1036. doi: 10.1016/0006-291x(89)90777-8. [DOI] [PubMed] [Google Scholar]
  32. KOWALSKI H. J., ABELMANN W. H. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest. 1953 Oct;32(10):1025–1033. doi: 10.1172/JCI102813. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Keppler D., Hagmann W., Rapp S., Denzlinger C., Koch H. K. The relation of leukotrienes to liver injury. Hepatology. 1985 Sep-Oct;5(5):883–891. doi: 10.1002/hep.1840050530. [DOI] [PubMed] [Google Scholar]
  34. Kramer R. M., Hession C., Johansen B., Hayes G., McGray P., Chow E. P., Tizard R., Pepinsky R. B. Structure and properties of a human non-pancreatic phospholipase A2. J Biol Chem. 1989 Apr 5;264(10):5768–5775. [PubMed] [Google Scholar]
  35. Krowka M. J., Cortese D. A. Hepatopulmonary syndrome: an evolving perspective in the era of liver transplantation. Hepatology. 1990 Jan;11(1):138–142. doi: 10.1002/hep.1840110123. [DOI] [PubMed] [Google Scholar]
  36. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  37. Lieberman F. L., Reynolds T. B. Plasma volume in cirrhosis of the liver: its relation of portal hypertension, ascites, and renal failure. J Clin Invest. 1967 Aug;46(8):1297–1308. doi: 10.1172/JCI105622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Lovett D. H., Sterzel R. B., Kashgarian M., Ryan J. L. Neutral proteinase activity produced in vitro by cells of the glomerular mesangium. Kidney Int. 1983 Feb;23(2):342–349. doi: 10.1038/ki.1983.25. [DOI] [PubMed] [Google Scholar]
  39. MURRAY J. F., DAWSON A. M., SHERLOCK S. Circulatory changes in chronic liver disease. Am J Med. 1958 Mar;24(3):358–367. doi: 10.1016/0002-9343(58)90322-x. [DOI] [PubMed] [Google Scholar]
  40. Marshall L. A., Roshak A. Coexistence of two biochemically distinct phospholipase A2 activities in human platelet, monocyte, and neutrophil. Biochem Cell Biol. 1993 Jul-Aug;71(7-8):331–339. doi: 10.1139/o93-050. [DOI] [PubMed] [Google Scholar]
  41. Mayer R. J., Marshall L. A. New insights on mammalian phospholipase A2(s); comparison of arachidonoyl-selective and -nonselective enzymes. FASEB J. 1993 Feb 1;7(2):339–348. doi: 10.1096/fasebj.7.2.8440410. [DOI] [PubMed] [Google Scholar]
  42. Moore K., Ward P. S., Taylor G. W., Williams R. Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome. Gastroenterology. 1991 Apr;100(4):1069–1077. doi: 10.1016/0016-5085(91)90284-r. [DOI] [PubMed] [Google Scholar]
  43. Märki F., Franson R. Endogenous suppression of neutral-active and calcium-dependent phospholipase A2 in human polymorphonuclear leukocytes. Biochim Biophys Acta. 1986 Nov 14;879(2):149–156. doi: 10.1016/0005-2760(86)90097-4. [DOI] [PubMed] [Google Scholar]
  44. Müller S., Seitz H. J. Cloning of a cDNA for the FAD-linked glycerol-3-phosphate dehydrogenase from rat liver and its regulation by thyroid hormones. Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10581–10585. doi: 10.1073/pnas.91.22.10581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Nakano T., Arita H. Enhanced expression of group II phospholipase A2 gene in the tissues of endotoxin shock rats and its suppression by glucocorticoid. FEBS Lett. 1990 Oct 29;273(1-2):23–26. doi: 10.1016/0014-5793(90)81042-m. [DOI] [PubMed] [Google Scholar]
  46. Nakano T., Ohara O., Teraoka H., Arita H. Group II phospholipase A2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells. FEBS Lett. 1990 Feb 12;261(1):171–174. doi: 10.1016/0014-5793(90)80663-4. [DOI] [PubMed] [Google Scholar]
  47. Nakazato Y., Simonson M. S., Herman W. H., Konieczkowski M., Sedor J. R. Interleukin-1 alpha stimulates prostaglandin biosynthesis in serum-activated mesangial cells by induction of a non-pancreatic (type II) phospholipase A2. J Biol Chem. 1991 Jul 25;266(21):14119–14127. [PubMed] [Google Scholar]
  48. Nicholls K. M., Shapiro M. D., Van Putten V. J., Kluge R., Chung H. M., Bichet D. G., Schrier R. W. Elevated plasma norepinephrine concentrations in decompensated cirrhosis. Association with increased secretion rates, normal clearance rates, and suppressibility by central blood volume expansion. Circ Res. 1985 Mar;56(3):457–461. doi: 10.1161/01.res.56.3.457. [DOI] [PubMed] [Google Scholar]
  49. Ohara N., Voelkel N. F., Chang S. W. Tissue eicosanoids and vascular permeability in rats with chronic biliary obstruction. Hepatology. 1993 Jul;18(1):111–118. [PubMed] [Google Scholar]
  50. Ohara O., Tamaki M., Nakamura E., Tsuruta Y., Fujii Y., Shin M., Teraoka H., Okamoto M. Dog and rat pancreatic phospholipases A2: complete amino acid sequences deduced from complementary DNAs. J Biochem. 1986 Mar;99(3):733–739. doi: 10.1093/oxfordjournals.jbchem.a135532. [DOI] [PubMed] [Google Scholar]
  51. Parker M. M., Shelhamer J. H., Natanson C., Alling D. W., Parrillo J. E. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med. 1987 Oct;15(10):923–929. doi: 10.1097/00003246-198710000-00006. [DOI] [PubMed] [Google Scholar]
  52. Patriarca P., Beckerdite S., Elsbach P. Phospholipases and phospholipid turnover in Escherichia coli spheroplasts. Biochim Biophys Acta. 1972 Apr 18;260(4):593–600. doi: 10.1016/0005-2760(72)90008-2. [DOI] [PubMed] [Google Scholar]
  53. Prytz H., Holst-Christensen J., Korner B., Liehr H. Portal venous and systemic endotoxaemia in patients without liver disease and systemic endotoxaemia in patients with cirrhosis. Scand J Gastroenterol. 1976;11(8):857–863. [PubMed] [Google Scholar]
  54. Raymond K. H., Lifschitz M. D. Effect of prostaglandins on renal salt and water excretion. Am J Med. 1986 Jan 17;80(1A):22–33. doi: 10.1016/0002-9343(86)90929-0. [DOI] [PubMed] [Google Scholar]
  55. Reeves J. T., Grover R. F. Blockade of acute hypoxic pulmonary hypertension by endotoxin. J Appl Physiol. 1974 Mar;36(3):328–332. doi: 10.1152/jappl.1974.36.3.328. [DOI] [PubMed] [Google Scholar]
  56. Rush B. D., Wilkinson K. F., Nichols N. M., Ochoa R., Brunden M. N., Ruwart M. J. Hepatic protection by 16, 16-dimethyl prostaglandin E2 (DMPG) against acute aflatoxin B1-induced injury in the rat. Prostaglandins. 1989 Jun;37(6):683–693. doi: 10.1016/0090-6980(89)90105-6. [DOI] [PubMed] [Google Scholar]
  57. Ruwart M. J., Rush B. D., Friedle N. M., Piper R. C., Kolaja G. J. Protective effects of 16,16-dimethyl PGE2 on the liver and kidney. Prostaglandins. 1981;21 (Suppl):97–102. doi: 10.1016/0090-6980(81)90124-6. [DOI] [PubMed] [Google Scholar]
  58. Sautebin L., Carnuccio R., Ialenti A., Di Rosa M. Lipocortin and vasocortin: two species of anti-inflammatory proteins mimicking the effects of glucocorticoids. Pharmacol Res. 1992 Jan;25(1):1–12. doi: 10.1016/s1043-6618(05)80058-1. [DOI] [PubMed] [Google Scholar]
  59. Schalkwijk C., Pfeilschifter J., Märki F., van den Bosch H. Interleukin-1 beta, tumor necrosis factor and forskolin stimulate the synthesis and secretion of group II phospholipase A2 in rat mesangial cells. Biochem Biophys Res Commun. 1991 Jan 15;174(1):268–275. doi: 10.1016/0006-291x(91)90515-9. [DOI] [PubMed] [Google Scholar]
  60. Schroeder E. T., Anderson G. H., Goldman S. H., Streeten D. H. Effect of blockade of angiotensin II on blood pressure, renin and aldosterone in cirrhosis. Kidney Int. 1976 Jun;9(6):511–519. doi: 10.1038/ki.1976.65. [DOI] [PubMed] [Google Scholar]
  61. Shiratori Y., Moriwaki H., Muto Y., Onishi H., Kato M., Asano F. Production of leukotriene B4 in parenchymal and sinusoidal cells of the liver in rats treated simultaneously with D-galactosamine and endotoxin. Gastroenterol Jpn. 1989 Dec;24(6):640–645. doi: 10.1007/BF02774162. [DOI] [PubMed] [Google Scholar]
  62. Stachura J., Tarnawski A., Ivey K. J., Mach T., Bogdal J., Szczudrawa J., klimczyk B. Prostaglandin protection of carbon tetrachloride-induced liver cell necrosis in the rat. Gastroenterology. 1981 Aug;81(2):211–217. [PubMed] [Google Scholar]
  63. Steiner M. R., Bomalaski J. S., Clark M. A. Responses of purified phospholipases A2 to phospholipase A2 activating protein (PLAP) and melittin. Biochim Biophys Acta. 1993 Feb 10;1166(1):124–130. doi: 10.1016/0005-2760(93)90292-h. [DOI] [PubMed] [Google Scholar]
  64. Tiegs G., Wendel A. Leukotriene-mediated liver injury. Biochem Pharmacol. 1988 Jul 1;37(13):2569–2573. doi: 10.1016/0006-2952(88)90248-1. [DOI] [PubMed] [Google Scholar]
  65. Uemura M., Buchholz U., Kojima H., Keppler A., Hafkemeyer P., Fukui H., Tsujii T., Keppler D. Cysteinyl leukotrienes in the urine of patients with liver diseases. Hepatology. 1994 Oct;20(4 Pt 1):804–812. doi: 10.1002/hep.1840200406. [DOI] [PubMed] [Google Scholar]
  66. Vishwanath B. S., Frey F. J., Bradbury M. J., Dallman M. F., Frey B. M. Glucocorticoid deficiency increases phospholipase A2 activity in rats. J Clin Invest. 1993 Oct;92(4):1974–1980. doi: 10.1172/JCI116791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Vishwanath B. S., Fux C. A., Uehlinger D. E., Frey B. M., Franson R. C., Frey F. J. Haemodialysis activates phospholipase A2 enzyme. Nephrol Dial Transplant. 1996 Jan;11(1):109–116. [PubMed] [Google Scholar]
  68. Wallner B. P., Mattaliano R. J., Hession C., Cate R. L., Tizard R., Sinclair L. K., Foeller C., Chow E. P., Browing J. L., Ramachandran K. L. Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. Nature. 1986 Mar 6;320(6057):77–81. doi: 10.1038/320077a0. [DOI] [PubMed] [Google Scholar]
  69. Wang A. M., Doyle M. V., Mark D. F. Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci U S A. 1989 Dec;86(24):9717–9721. doi: 10.1073/pnas.86.24.9717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Wendel A., Tiegs G. Leukotriene D4 mediates galactosamine/endotoxin-induced hepatitis in mice. Biochem Pharmacol. 1987 Jun 15;36(12):1867–1867. doi: 10.1016/0006-2952(87)90482-5. [DOI] [PubMed] [Google Scholar]
  71. Wong F., Massie D., Hsu P., Dudley F. Dose-dependent effects of oral misoprostol on renal function in alcoholic cirrhosis. Gastroenterology. 1994 Mar;106(3):658–663. doi: 10.1016/0016-5085(94)90699-8. [DOI] [PubMed] [Google Scholar]
  72. Zipser R. D., Hoefs J. C., Speckart P. F., Zia P. K., Horton R. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab. 1979 Jun;48(6):895–900. doi: 10.1210/jcem-48-6-895. [DOI] [PubMed] [Google Scholar]
  73. Zipser R. D., Radvan G. H., Kronborg I. J., Duke R., Little T. E. Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology. 1983 Apr;84(4):697–703. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES